Rocket Pharmaceuticals Stock Performance
| RCKT Stock | USD 3.25 0.01 0.31% |
Rocket Pharmaceuticals has a performance score of 3 on a scale of 0 to 100. The company holds a Beta of 1.38, which implies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Rocket Pharmaceuticals will likely underperform. Rocket Pharmaceuticals right now holds a risk of 3.9%. Please check Rocket Pharmaceuticals value at risk, and the relationship between the jensen alpha and skewness , to decide if Rocket Pharmaceuticals will be following its historical price patterns.
Risk-Adjusted Performance
Soft
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Rocket Pharmaceuticals are ranked lower than 3 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively uncertain forward-looking signals, Rocket Pharmaceuticals may actually be approaching a critical reversion point that can send shares even higher in March 2026. ...more
Actual Historical Performance (%)
One Day Return 0.31 | Five Day Return 4.84 | Year To Date Return (6.07) | Ten Year Return (87.82) | All Time Return (86.46) |
Last Split Factor 1:4 | Dividend Date 2018-01-05 | Last Split Date 2018-01-05 |
1 | Is Rocket Pharmaceuticals Inc. stock oversold or undervalued - Weekly Investment Report Growth Oriented Trading Recommendations - newser.com | 11/17/2025 |
2 | Bank of America Cuts Rocket Pharmaceuticals Price Target to 8.00 | 11/21/2025 |
3 | Is Rocket Pharmaceuticals Inc. stock among top earnings plays - Earnings Overview Report Capital Efficiency Focused Strategies - Newser | 12/01/2025 |
4 | Rocket Pharmaceuticals Stock Target Reduced Following Q3 2025 Update on Cash Position - Insider Monkey | 12/15/2025 |
5 | Rocket Pharmaceuticals Leads Our Trio Of Penny Stock Contenders - Yahoo Finance | 12/17/2025 |
6 | Acquisition by Bjork Elisabeth of 10000 shares of Rocket Pharmaceuticals at 3.44 subject to Rule 16b-3 | 01/02/2026 |
7 | Earnings Beat Can Rocket Pharmaceuticals Inc expand into new markets - 2025 Analyst Calls Risk Managed Investment Entry Signals - baoquankhu1.vn | 01/12/2026 |
| Begin Period Cash Flow | 57.3 M | |
| Total Cashflows From Investing Activities | 131.7 M |
Rocket Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 304.00 in Rocket Pharmaceuticals on November 15, 2025 and sell it today you would earn a total of 21.00 from holding Rocket Pharmaceuticals or generate 6.91% return on investment over 90 days. Rocket Pharmaceuticals is currently generating 0.1857% in daily expected returns and assumes 3.9035% risk (volatility on return distribution) over the 90 days horizon. In different words, 35% of stocks are less volatile than Rocket, and 97% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Rocket Pharmaceuticals Target Price Odds to finish over Current Price
The tendency of Rocket Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 3.25 | 90 days | 3.25 | about 70.49 |
Based on a normal probability distribution, the odds of Rocket Pharmaceuticals to move above the current price in 90 days from now is about 70.49 (This Rocket Pharmaceuticals probability density function shows the probability of Rocket Stock to fall within a particular range of prices over 90 days) .
Rocket Pharmaceuticals Price Density |
| Price |
Predictive Modules for Rocket Pharmaceuticals
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Rocket Pharmaceuticals. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Rocket Pharmaceuticals Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Rocket Pharmaceuticals is not an exception. The market had few large corrections towards the Rocket Pharmaceuticals' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Rocket Pharmaceuticals, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Rocket Pharmaceuticals within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 0 | |
β | Beta against Dow Jones | 1.38 | |
σ | Overall volatility | 0.26 | |
Ir | Information ratio | 0.01 |
Rocket Pharmaceuticals Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Rocket Pharmaceuticals for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Rocket Pharmaceuticals can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Rocket Pharmaceuticals had very high historical volatility over the last 90 days | |
| Net Loss for the year was (258.75 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Rocket Pharmaceuticals currently holds about 321.37 M in cash with (209.72 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.87, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Rocket Pharmaceuticals has a frail financial position based on the latest SEC disclosures | |
| Over 90.0% of the company shares are owned by institutional investors |
Rocket Pharmaceuticals Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Rocket Stock often depends not only on the future outlook of the current and potential Rocket Pharmaceuticals' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Rocket Pharmaceuticals' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 94.8 M | |
| Cash And Short Term Investments | 372.3 M |
Rocket Pharmaceuticals Fundamentals Growth
Rocket Stock prices reflect investors' perceptions of the future prospects and financial health of Rocket Pharmaceuticals, and Rocket Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Rocket Stock performance.
| Return On Equity | -0.75 | ||||
| Return On Asset | -0.41 | ||||
| Current Valuation | 154.01 M | ||||
| Shares Outstanding | 108.22 M | ||||
| Price To Book | 1.12 X | ||||
| EBITDA | (247.49 M) | ||||
| Net Income | (258.75 M) | ||||
| Cash And Equivalents | 321.37 M | ||||
| Cash Per Share | 4.87 X | ||||
| Total Debt | 25.5 M | ||||
| Debt To Equity | 0.06 % | ||||
| Current Ratio | 13.41 X | ||||
| Book Value Per Share | 2.90 X | ||||
| Cash Flow From Operations | (209.72 M) | ||||
| Earnings Per Share | (2.25) X | ||||
| Market Capitalization | 351.72 M | ||||
| Total Asset | 527.7 M | ||||
| Retained Earnings | (1.22 B) | ||||
| Working Capital | 337.5 M | ||||
About Rocket Pharmaceuticals Performance
Assessing Rocket Pharmaceuticals' fundamental ratios provides investors with valuable insights into Rocket Pharmaceuticals' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Rocket Pharmaceuticals is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.50) | (0.53) | |
| Return On Capital Employed | (0.65) | (0.68) | |
| Return On Assets | (0.44) | (0.46) | |
| Return On Equity | (0.64) | (0.67) |
Things to note about Rocket Pharmaceuticals performance evaluation
Checking the ongoing alerts about Rocket Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Rocket Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Rocket Pharmaceuticals had very high historical volatility over the last 90 days | |
| Net Loss for the year was (258.75 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Rocket Pharmaceuticals currently holds about 321.37 M in cash with (209.72 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.87, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Rocket Pharmaceuticals has a frail financial position based on the latest SEC disclosures | |
| Over 90.0% of the company shares are owned by institutional investors |
- Analyzing Rocket Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Rocket Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Rocket Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Rocket Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Rocket Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Rocket Pharmaceuticals' stock. These opinions can provide insight into Rocket Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Rocket Stock Analysis
When running Rocket Pharmaceuticals' price analysis, check to measure Rocket Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Rocket Pharmaceuticals is operating at the current time. Most of Rocket Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Rocket Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Rocket Pharmaceuticals' price. Additionally, you may evaluate how the addition of Rocket Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.